Top 10 unpaywall.org Competitors

sci-hub.se

sci-hub website. get free access to academic journals. download research papers for free from sciencedirect, ieee, wiley, springer, nature and others

openaccessbutton.org

Free, legal research articles delivered instantly or automatically requested from authors.

oa.mg

What is a Ph.D. in Sociology? A research doctorate training scholars in social theory and research methods, typically fully funded and highly selective, often admitting under 10% of applicants.

doaj.org

DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

scienceopen.com

Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 mont

semanticscholar.org

Semantic Scholar uses groundbreaking AI and engineering to understand the semantics of scientific literature to help Scholars discover relevant research.

arxiv.org

We perform a behavioral experiment of karma, a class of mechanisms for repeated resource allocation with attractive fairness and efficiency properties, in theory. Individuals in these mechanisms bid non-tradable credits that flow from resource consumers to yielders, like karma. Human subjects recruited on Amazon MTurk are repeatedly and randomly paired to bid karma according to time-varying and stochastic individual preferences or urgency to acquire resources. Treatments varied in the dynamic urgency process (frequent moderate urgency versus sporadic high urgency) and the richness of the bidding scheme (binary versus full range). Results are benchmarked against random allocation, and karma achieves a (almost) Pareto improvement over random, despite the MTurk subjects deviating significantly from the theoretically optimal Nash bidding policy. Maximum improvement is attained by subjects that deviate from Nash by up to one karma bid unit on average, and positive improvement is attained with average deviations of up to 3-4 bid units. These findings hold across all treatments, among which no significant differences are found, with the exception of the sporadic high urgency process with binary bidding treatment being (weakly) favorable over others. These results offer behaviorally robust lower bounds for the expected performance of karma in human populations. They also provide guidance for future testing and implementation of karma mechanisms in the real world.

researchgate.net

Access 160+ million publication pages and connect with 25+ million researchers. Join for free and gain visibility by uploading your research.

link.springer.com

providing access to millions of research articles and chapters from science, technology and medicine, and humanities and social sciences